Bright Minds Biosciences Q2 EPS C$(0.39) Up From C$(1.12) YoY
Portfolio Pulse from Benzinga Newsdesk
Bright Minds Biosciences (NASDAQ:DRUG) reported Q2 losses of C$(0.39) per share, a 65.18% improvement from C$(1.12) per share losses in the same period last year.
August 15, 2023 | 10:37 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bright Minds Biosciences reported a 65.18% improvement in its Q2 losses YoY. The losses per share decreased from C$(1.12) to C$(0.39).
Bright Minds Biosciences reported a significant improvement in its Q2 losses compared to the same period last year. This indicates a positive financial performance which could potentially lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100